Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis
Clinical Cardiology and Cardiovascular Interventions · 07.05.2026 · 09 (07) · 01-06
DOI: 10.31579/2641-0419/573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology and Cardiovascular Interventions, online erschienen am 07.05.2026. Verfasst von Nasser Mikhail.
Abstract (Originalsprache)
Apolipoprotein C3 (ApoC3) is a glycoprotein that normally increases levels of plasma triglycerides. Thus, Apo C3 inhibitors such as olezarsen and plozasiran result in reduction of triglycerides levels. In 2 phase 3 clinical trials of patients having familial chylomicronemia syndrome (FCS), olezarsen 80 mg administered subcutaneously every 4 weeks decreased triglycerides by -43.5 % (95% CI, -69.1 to -17.9; P
Zitieren
APA
Mikhail, N. (2026). Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis. Clinical Cardiology and Cardiovascular Interventions, 09(07), 01-06. https://doi.org/10.31579/2641-0419/573
Vancouver
Mikhail N. Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis. Clinical Cardiology and Cardiovascular Interventions. 2026;09(07):01-06. doi:10.31579/2641-0419/573
BibTeX
@article{Mikhail2026,
author = {Mikhail, Nasser},
title = {Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis},
journal = {Clinical Cardiology and Cardiovascular Interventions},
year = {2026},
volume = {09},
number = {07},
pages = {01--06},
doi = {10.31579/2641-0419/573}
}
EUVIMED